



Ref: FOIA Reference 2018/19-060

Royal Stoke University Hospital
Quality, Safety and Compliance Department
Newcastle Road
Stoke-on-Trent
Staffordshire
ST4 6QG

Date: 8th May 2018

Tel: 01782 676474
Email foi@uhn.nhs.uk

Dear

I am writing in response to your email dated 27th April 2018 requesting information under the Freedom of Information Act (2000) regarding free of charge drug stock.

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 Has your Trust accepted or is it currently accepting manufacturer provision of free of charge drug stock between licensing and NICE funding?

[Yes/No]

A1 Yes, if available.

Q2 Has your Trust accepted or is it currently accepting the following list of drugs in psoriasis:

- Brodalumab [Kyntheum] [Yes/No]
- Guselkumab [Tremfya] [Yes/No]
- Ixekizumab [Taltz] [Yes/No]
- Secukinumab [Cosentyx] [Yes/No]

A2 Please see below:

Brodalumab [Kyntheum]	No
Guselkumab [Tremfya]	No
Ixekizumab [Taltz]	[Yes] usage in dermatology (may not all be psoriasis use)
Secukinumab [Cosentyx]	[Yes] usage in dermatology (may not all be psoriasis use)

Q3 Has your Trust accepted or is it currently accepting the following list of drugs in Rheumatoid Arthritis:

- Tofacitinib [Xeljanz] [Yes/No]
- Baricitinib [Olumiant] [Yes/No]
- Golimumab [Simponi] [Yes/No]

- Certolizumab [Cimzia] [Yes/No]
- Apremilast [Otezla] [Yes/No]
- Tocilizumab [Ro Actemra] [Yes/No]

A3 Please see below:

Tofacitinib [Xeljanz]	[No]
Baricitinib [Olumiant]	[No]
Golimumab [Simponi]	[No]
Certolizumab [Cimzia]	[No]
Apremilast [Otezla]	[No]
Tocilizumab [Ro Actemra]	[No]

Q4 Has your Trust accepted or is it currently accepting the following list of drugs in Ankylosing Spondylitis or Psoriatic Arthritis:

Secukinumab [Cosentyx] [Yes/No]

A4 No

Q5 Has your Trust accepted or is it currently accepting the following list of drugs in Ulcerative Colitis:

Golimumab [Simponi] [Yes/No]

A5 Yes, however usage in gastroenterology (May not all be ulcerative colitis)

Q6 If your Trust has not accepted manufacturer provision of free of charge drug stock, what have been the reasons for this? [.....]

A6 Not applicable

Q7 In future, will your Trust be able to accept manufacturer provision of free of charge drug stock? [Yes/No]

A7 Each scheme would be individually considered.

Q8 What is the preferred distribution channel for the provision of free of charge drug stock?

- Homecare [Yes/No]
- Delivered directly to hospital/Trust [Yes/No]
- Other (please provide details) [.....]

A8 Please see below:

• Homecare	no
• Delivered directly to hospital/Trust	no
• Other (please provide details)	whatever distribution channel suits patient/drug/scheme]

Q9 For how long is free of charge drug stock typically provided for each patient?

- first dose [Yes/No]
- first month [Yes/No]
- first 3 months [Yes/No]
- Other [.....]

A9 Please see below:

• first dose	
• first month	
• first 3 months	
• Other	varies with drug/scheme

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 676474.

Yours,

A handwritten signature in black ink, consisting of a large, loopy initial 'M' followed by a horizontal line.

Mojgan Casillas
Interim Information Governance Manager